Helene Kildegaard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Helene Kildegaard has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Anton Pottegård
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark Odense Denmark
10 shared publications - Heidi Sonne
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark Odense Denmark
7 shared publications - Rikke Wesselhoeft
Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark
7 shared publications - Mette Bliddal
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark
5 shared publications Anton Pottegård
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark
4 shared publications- Anna Sofie Hansen
Aalborg University Hospital
3 shared publications
Latest Publications
- Open Access
- 25 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Impact of Semaglutide Introduction on the Use of Concomitant Medications: An Interrupted Time Series
Aims: To evaluate the impact of semaglutide initiation for weight management on the use of concomitant medications commonly prescribed for obesity‐related comorbidities. Materials and Methods: We conducted a nationwide interrupted time series study using data from Danish registers, including adults initiating semaglutide for weight management between 12/2022 and 12/2024. Monthly prescriptions for 10 medication classes were analysed in the 24 months before and 12 months after initiation. Effects at 12 months were expressed as rate ratios (RRs) comparing observed values with expected values based on pre‐initiation trends. Results: Among 189 392 semaglutide initiators (68% women; median age 50 years), prescription volumes at 12 months declined and were lower than projected from pre‐initiation trends for antiasthmatics (RR: 0.82, 95% confidence interval 0.79–0.86), topical corticosteroids (0.91, 0.87–0.96), antipsoriatics (0.91, 0.83–1.00), analgesics (0.93, 0.90–0.96), antidepressants (0.93, 0.89–0.98) and topical antifungal formulations (0.92, 0.86–0.99). Antihypertensive prescriptions continued to rise after semaglutide initiation, but more slowly than projected (0.92, 0.89–0.95). Glucose‐lowering medications declined (0.87, 0.82–0.92), mainly non‐insulin agents, but a similar reduction was observed in the negative control cohort. Anxiolytic use increased (1.16, 1.08–1.24) and remained elevated at 2 years. Changes in lipid‐modifying agents and medications for gastric acid disorders were small or transient. Conclusions: Semaglutide initiation for weight management was associated with reduced use of several concomitant medications for obesity‐related comorbidities, while anxiolytic use increased. Changes in other therapeutic classes were limited. These findings suggest that semaglutide treatment may influence overall medication use and support continued monitoring of prescribing patterns during therapy.
- 25 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Open AccessImpact of Semaglutide Introduction on the Use of Concomitant Medications: An Interrupted Time Series
Aims: To evaluate the impact of semaglutide initiation for weight management on the use of concomitant medications commonly prescribed for obesity‐related comorbidities. Materials and Methods: We conducted a nationwide interrupted time series study using data from Danish registers, including adults initiating semaglutide for weight management between 12/2022 and 12/2024. Monthly prescriptions for 10 medication classes were analysed in the 24 months before and 12 months after initiation. Effects at 12 months were expressed as rate ratios (RRs) comparing observed values with expected values based on pre‐initiation trends. Results: Among 189 392 semaglutide initiators (68% women; median age 50 years), prescription volumes at 12 months declined and were lower than projected from pre‐initiation trends for antiasthmatics (RR: 0.82, 95% confidence interval 0.79–0.86), topical corticosteroids (0.91, 0.87–0.96), antipsoriatics (0.91, 0.83–1.00), analgesics (0.93, 0.90–0.96), antidepressants (0.93, 0.89–0.98) and topical antifungal formulations (0.92, 0.86–0.99). Antihypertensive prescriptions continued to rise after semaglutide initiation, but more slowly than projected (0.92, 0.89–0.95). Glucose‐lowering medications declined (0.87, 0.82–0.92), mainly non‐insulin agents, but a similar reduction was observed in the negative control cohort. Anxiolytic use increased (1.16, 1.08–1.24) and remained elevated at 2 years. Changes in lipid‐modifying agents and medications for gastric acid disorders were small or transient. Conclusions: Semaglutide initiation for weight management was associated with reduced use of several concomitant medications for obesity‐related comorbidities, while anxiolytic use increased. Changes in other therapeutic classes were limited. These findings suggest that semaglutide treatment may influence overall medication use and support continued monitoring of prescribing patterns during therapy.
- Open Access
Variation in psychiatric diagnoses and use of psychotropic medication among children, adolescents, and young adults in Denmark
Background: Psychiatric diagnoses and psychotropic medication use among children, adolescents, and young adults have increased in high-income countries, with concerns about geographic variation. We described national trends and geographic variation in Denmark from 2010 to 2025 and developed an interactive online tool to explore these patterns. Methods: We conducted a nationwide, descriptive, repeated cross-sectional register-based study of all Danish residents aged 0-24 years in 2010-2025 (n=2,930,744), using the Danish National Patient Registry and the Danish National Prescription Registry. We estimated annual incidence, prevalence, and, for selected diagnoses, lifetime prevalence, by age and sex, and age- and sex-standardised rates across regions, health councils, and municipalities. We assessed geographic variation using deviations from national means, coefficients of variation, Gini coefficients, and funnel plots. Findings: Psychiatric diagnoses and psychotropic medication use increased from 2010 to 2025. The annual prevalence of attention-deficit hyperactivity disorder (ADHD) increased from 0·41 to 2·3 per 100 individuals, autism spectrum disorders from 0·20 to 1·2, and melatonin use from 0·14 to 3·0. ADHD and autism spectrum disorders were more prevalent among boys and anxiety disorders among girls. Sertraline use was also more prevalent among girls. Geographic variation was observed across diagnoses and psychotropic medications at regional, health council, and municipal levels. For example, lifetime prevalence of autism ranged from 1·3 to 5·9 per 100 across municipalities, and in 2025 regional coefficients of variation ranged from 0·11 (sertraline) to 0·41 (atomoxetine). Results can be explored in the interactive online tool ( https://bupstat.sdu.dk/?lang=en ). Interpretation: Psychiatric diagnoses and psychotropic medication use increased among Danish children, adolescents, and young adults, with marked geographic variation. Descriptive data cannot establish the causes of this variation, but the findings identify areas for further review and support continued monitoring. Funding: Best for Us project ( www.bedstforos.dk ), funded by the Novo Nordisk Foundation (NNF24SA0093635) and the Obel Family Foundation (69348). Research in context: Evidence before this study: We searched PubMed on 25 September 2026 without date or language restrictions, using two search strings ( Appendix Text 1 ). One search string combined search terms for psychiatric disorders and psychotropic medications, children, adolescents, and young adults, and geographic variation. The other search string combined similar population and condition terms with time trends and Denmark or other Nordic countries. We supplemented these with reference lists of key publications, health atlas websites, and national reports. Existing evidence shows substantial increases in psychiatric diagnoses and psychotropic medication use among children and adolescents in high-income countries over the past two decades, with particularly marked rises in attention-deficit hyperactivity disorder (ADHD), autism spectrum disorders, and use of ADHD medications, antidepressants, and melatonin. Studies show considerable geographic variation in diagnostic and prescribing practices that differences in underlying morbidity cannot fully account for. Other countries have produced health atlases examining geographic variation in child and adolescent mental healthcare. However, no comparable nationwide analysis covering both psychiatric diagnoses and psychotropic medication use across multiple geographic levels has previously been conducted in Denmark. The identified studies were predominantly observational and register-based. Nationwide health registries provide high-quality data, but the observational nature limits causal inference about the mechanisms underlying the observed variation. Added value of this study: This study provides the first nationwide, comprehensive mapping of both psychiatric diagnoses and psychotropic medication use among Danish children, adolescents, and young adults over a 16-year period. By applying standardised measures of geographic variation, including coefficients of variation, Lorenz curves, and Gini coefficients, across a broad range of diagnostic categories and medication groups simultaneously, this study extends previous Danish and Nordic work. The accompanying interactive online tool enables dynamic exploration of temporal and geographic patterns and supports ongoing monitoring and dissemination of findings beyond the research community. Implications of all the available evidence: The substantial geographic variation observed across diagnostic and prescribing practices, combined with the rising prevalence of psychiatric diagnoses and psychotropic medication use, highlights the need for continued monitoring of child and adolescent mental healthcare in Denmark. The findings provide a foundation for targeted quality-improvement initiatives, resource planning, and closer alignment of diagnostic and prescribing practice at the regional and municipal levels. Future research should examine the mechanisms underlying geographic variation, including the role of access to services, local clinical cultures, and socioeconomic factors, and evaluate the impact of initiatives to reduce unwarranted variation.
Open AccessVariation in psychiatric diagnoses and use of psychotropic medication among children, adolescents, and young adults in Denmark
Background: Psychiatric diagnoses and psychotropic medication use among children, adolescents, and young adults have increased in high-income countries, with concerns about geographic variation. We described national trends and geographic variation in Denmark from 2010 to 2025 and developed an interactive online tool to explore these patterns. Methods: We conducted a nationwide, descriptive, repeated cross-sectional register-based study of all Danish residents aged 0-24 years in 2010-2025 (n=2,930,744), using the Danish National Patient Registry and the Danish National Prescription Registry. We estimated annual incidence, prevalence, and, for selected diagnoses, lifetime prevalence, by age and sex, and age- and sex-standardised rates across regions, health councils, and municipalities. We assessed geographic variation using deviations from national means, coefficients of variation, Gini coefficients, and funnel plots. Findings: Psychiatric diagnoses and psychotropic medication use increased from 2010 to 2025. The annual prevalence of attention-deficit hyperactivity disorder (ADHD) increased from 0·41 to 2·3 per 100 individuals, autism spectrum disorders from 0·20 to 1·2, and melatonin use from 0·14 to 3·0. ADHD and autism spectrum disorders were more prevalent among boys and anxiety disorders among girls. Sertraline use was also more prevalent among girls. Geographic variation was observed across diagnoses and psychotropic medications at regional, health council, and municipal levels. For example, lifetime prevalence of autism ranged from 1·3 to 5·9 per 100 across municipalities, and in 2025 regional coefficients of variation ranged from 0·11 (sertraline) to 0·41 (atomoxetine). Results can be explored in the interactive online tool ( https://bupstat.sdu.dk/?lang=en ). Interpretation: Psychiatric diagnoses and psychotropic medication use increased among Danish children, adolescents, and young adults, with marked geographic variation. Descriptive data cannot establish the causes of this variation, but the findings identify areas for further review and support continued monitoring. Funding: Best for Us project ( www.bedstforos.dk ), funded by the Novo Nordisk Foundation (NNF24SA0093635) and the Obel Family Foundation (69348). Research in context: Evidence before this study: We searched PubMed on 25 September 2026 without date or language restrictions, using two search strings ( Appendix Text 1 ). One search string combined search terms for psychiatric disorders and psychotropic medications, children, adolescents, and young adults, and geographic variation. The other search string combined similar population and condition terms with time trends and Denmark or other Nordic countries. We supplemented these with reference lists of key publications, health atlas websites, and national reports. Existing evidence shows substantial increases in psychiatric diagnoses and psychotropic medication use among children and adolescents in high-income countries over the past two decades, with particularly marked rises in attention-deficit hyperactivity disorder (ADHD), autism spectrum disorders, and use of ADHD medications, antidepressants, and melatonin. Studies show considerable geographic variation in diagnostic and prescribing practices that differences in underlying morbidity cannot fully account for. Other countries have produced health atlases examining geographic variation in child and adolescent mental healthcare. However, no comparable nationwide analysis covering both psychiatric diagnoses and psychotropic medication use across multiple geographic levels has previously been conducted in Denmark. The identified studies were predominantly observational and register-based. Nationwide health registries provide high-quality data, but the observational nature limits causal inference about the mechanisms underlying the observed variation. Added value of this study: This study provides the first nationwide, comprehensive mapping of both psychiatric diagnoses and psychotropic medication use among Danish children, adolescents, and young adults over a 16-year period. By applying standardised measures of geographic variation, including coefficients of variation, Lorenz curves, and Gini coefficients, across a broad range of diagnostic categories and medication groups simultaneously, this study extends previous Danish and Nordic work. The accompanying interactive online tool enables dynamic exploration of temporal and geographic patterns and supports ongoing monitoring and dissemination of findings beyond the research community. Implications of all the available evidence: The substantial geographic variation observed across diagnostic and prescribing practices, combined with the rising prevalence of psychiatric diagnoses and psychotropic medication use, highlights the need for continued monitoring of child and adolescent mental healthcare in Denmark. The findings provide a foundation for targeted quality-improvement initiatives, resource planning, and closer alignment of diagnostic and prescribing practice at the regional and municipal levels. Future research should examine the mechanisms underlying geographic variation, including the role of access to services, local clinical cultures, and socioeconomic factors, and evaluate the impact of initiatives to reduce unwarranted variation.
- Open Access
Effects of Reimbursement Policy Change on Utilization of Injectable Semaglutide for Type 2 Diabetes and on Glycemic Control Among Discontinuers: A Danish Nationwide Cohort Study
Objectives: To evaluate the impact of reimbursement restrictions for glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes, introduced in Denmark in November 2024, on injectable semaglutide (Ozempic®) utilization patterns and subsequent HbA1c changes among discontinuers. Design: Nationwide registry-based cohort study. Setting: Denmark. Participants: Adults treated with injectable semaglutide for diabetes (January 2018 to December 2025). Main outcome measures: We described temporal patterns in injectable semaglutide use before and after the policy change. Among semaglutide continuers after the policy change, we assessed whether continuation met a key criterion in the new policy: non-feasibility of sodium-glucose cotransporter 2 inhibitor use and high cardiovascular risk. We characterized semaglutide discontinuers around the policy implementation (March 2024 to November 2024) and subsequent treatment switches. Among discontinuers, we evaluated HbA1c changes and performed interrupted time series (ITS) analyses. Results: Following the policy change, use of injectable semaglutide declined modestly before subsequently increasing. Among 61,120 individuals classified as semaglutide continuers, 27,143 (44%) were already using an SGLT2i. Of the remaining 33,977 (56%), only 1,862 (5.5%) met a key reimbursement criterion (i.e., non-feasibility of SGLT2i use and high cardiovascular risk). Among 79,305 individuals with a semaglutide fill between March 2024 and November 2024, 22,096 (28%) were classified as discontinuers. Within six months, ∼40% of discontinuers switched to other glucose-lowering therapies, most commonly SGLT2is (24%). 37% of discontinuers later reinitiated semaglutide. Among individuals with an on-treatment HbA1c measurement (within 12 months before their last semaglutide fill) and an off-treatment HbA1c measurement (6-12 months after their last semaglutide fill) (n=13,017), mean HbA1c increased from 49 to 57 mmol/mol (mean change +7.4 mmol/mol, 95% CI 7.2-7.6). ITS analysis showed that HbA1c increased by 5.9 mmol/mol (95% CI 5.1-6.7) at six months post-discontinuation, which attenuated to 3.1 mmol/mol (95% CI 2.2-4.1) at 12 months; raw monthly means (not included in the ITS model) suggested this persisted through 18 months. Conclusions: Following the policy change, population-level use of injectable semaglutide declined modestly before increasing again. Most discontinuers did not initiate another glucose-lowering therapy and experienced an increase in HbA1c that did not fully return to pre-discontinuation levels during follow-up. What is already known on this topic: The rapid uptake and high costs of GLP-1 receptor agonists, including injectable semaglutide for diabetes (Ozempic®), have prompted health systems to consider how access to these treatments should be prioritized and reimbursed. Little is known about how reimbursement restrictions on GLP-1 receptor agonists influence treatment patterns and glycemic control after treatment discontinuation. What this study adds: Following a national reimbursement restriction in Denmark, more than one in four patients discontinued injectable semaglutide for diabetes, and among those who switched treatment, SGLT2 inhibitors were the most common alternative, while most discontinuers did not initiate another glucose-lowering drug within six months. Approximately one in three discontinuers reinitiated their semaglutide therapy more than six months after stopping. Discontinuation of injectable semaglutide for diabetes was followed by a rise in HbA1c that, despite improvement over time, did not return to pre-discontinuation levels over 18 months, highlighting a potential clinical consequence of restricting access to an effective glucose-lowering treatment option.
Open AccessEffects of Reimbursement Policy Change on Utilization of Injectable Semaglutide for Type 2 Diabetes and on Glycemic Control Among Discontinuers: A Danish Nationwide Cohort Study
Objectives: To evaluate the impact of reimbursement restrictions for glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes, introduced in Denmark in November 2024, on injectable semaglutide (Ozempic®) utilization patterns and subsequent HbA1c changes among discontinuers. Design: Nationwide registry-based cohort study. Setting: Denmark. Participants: Adults treated with injectable semaglutide for diabetes (January 2018 to December 2025). Main outcome measures: We described temporal patterns in injectable semaglutide use before and after the policy change. Among semaglutide continuers after the policy change, we assessed whether continuation met a key criterion in the new policy: non-feasibility of sodium-glucose cotransporter 2 inhibitor use and high cardiovascular risk. We characterized semaglutide discontinuers around the policy implementation (March 2024 to November 2024) and subsequent treatment switches. Among discontinuers, we evaluated HbA1c changes and performed interrupted time series (ITS) analyses. Results: Following the policy change, use of injectable semaglutide declined modestly before subsequently increasing. Among 61,120 individuals classified as semaglutide continuers, 27,143 (44%) were already using an SGLT2i. Of the remaining 33,977 (56%), only 1,862 (5.5%) met a key reimbursement criterion (i.e., non-feasibility of SGLT2i use and high cardiovascular risk). Among 79,305 individuals with a semaglutide fill between March 2024 and November 2024, 22,096 (28%) were classified as discontinuers. Within six months, ∼40% of discontinuers switched to other glucose-lowering therapies, most commonly SGLT2is (24%). 37% of discontinuers later reinitiated semaglutide. Among individuals with an on-treatment HbA1c measurement (within 12 months before their last semaglutide fill) and an off-treatment HbA1c measurement (6-12 months after their last semaglutide fill) (n=13,017), mean HbA1c increased from 49 to 57 mmol/mol (mean change +7.4 mmol/mol, 95% CI 7.2-7.6). ITS analysis showed that HbA1c increased by 5.9 mmol/mol (95% CI 5.1-6.7) at six months post-discontinuation, which attenuated to 3.1 mmol/mol (95% CI 2.2-4.1) at 12 months; raw monthly means (not included in the ITS model) suggested this persisted through 18 months. Conclusions: Following the policy change, population-level use of injectable semaglutide declined modestly before increasing again. Most discontinuers did not initiate another glucose-lowering therapy and experienced an increase in HbA1c that did not fully return to pre-discontinuation levels during follow-up. What is already known on this topic: The rapid uptake and high costs of GLP-1 receptor agonists, including injectable semaglutide for diabetes (Ozempic®), have prompted health systems to consider how access to these treatments should be prioritized and reimbursed. Little is known about how reimbursement restrictions on GLP-1 receptor agonists influence treatment patterns and glycemic control after treatment discontinuation. What this study adds: Following a national reimbursement restriction in Denmark, more than one in four patients discontinued injectable semaglutide for diabetes, and among those who switched treatment, SGLT2 inhibitors were the most common alternative, while most discontinuers did not initiate another glucose-lowering drug within six months. Approximately one in three discontinuers reinitiated their semaglutide therapy more than six months after stopping. Discontinuation of injectable semaglutide for diabetes was followed by a rise in HbA1c that, despite improvement over time, did not return to pre-discontinuation levels over 18 months, highlighting a potential clinical consequence of restricting access to an effective glucose-lowering treatment option.
- Open Access
- 30 August 2026
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 139 (4) , e70298
Regional Variation in ADHD Treatment and Diagnosis Among Children and Adolescents in Denmark
Geographic variation in ADHD treatment and diagnosis among children and adolescents is well documented, yet the system‐level factors driving such differences remain poorly understood. We examined nationwide patterns of ADHD medication use and diagnoses in Denmark in 2024 and assessed whether municipal socioeconomy, regional hospital waiting times or private child psychiatrist capacity contributed to geographic variation. In this register‐based cross‐sectional study, we included all Danish residents aged 4–17 years using data from national registers. Pharmacological treatment was defined as at least one redeemed prescription for ADHD drugs, and diagnosis was defined as at least one hospital contact with ICD‐10 codes F90.x/F98.8. Prevalence was calculated overall and stratified by sex and age, with associations explored using Spearman's rank correlations and regression analyses. ADHD medication prevalence varied sixfold across municipalities (9.6–58 per 1000), with parallel variation in diagnoses (15–74 per 1000) and the largest differences observed among adolescents. Municipal socioeconomic status was weakly and inversely correlated with medication use (ρ = −0.20, p = 0.049), but not diagnoses. Neither waiting times nor specialist capacity was significantly associated with either outcome. Marked geographic variation in ADHD medication use and diagnoses persists in Denmark despite a uniform healthcare framework, and appears largely unexplained by the system‐level factors examined.
- 30 August 2026
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 139 (4) , e70298
Open AccessRegional Variation in ADHD Treatment and Diagnosis Among Children and Adolescents in Denmark
Geographic variation in ADHD treatment and diagnosis among children and adolescents is well documented, yet the system‐level factors driving such differences remain poorly understood. We examined nationwide patterns of ADHD medication use and diagnoses in Denmark in 2024 and assessed whether municipal socioeconomy, regional hospital waiting times or private child psychiatrist capacity contributed to geographic variation. In this register‐based cross‐sectional study, we included all Danish residents aged 4–17 years using data from national registers. Pharmacological treatment was defined as at least one redeemed prescription for ADHD drugs, and diagnosis was defined as at least one hospital contact with ICD‐10 codes F90.x/F98.8. Prevalence was calculated overall and stratified by sex and age, with associations explored using Spearman's rank correlations and regression analyses. ADHD medication prevalence varied sixfold across municipalities (9.6–58 per 1000), with parallel variation in diagnoses (15–74 per 1000) and the largest differences observed among adolescents. Municipal socioeconomic status was weakly and inversely correlated with medication use (ρ = −0.20, p = 0.049), but not diagnoses. Neither waiting times nor specialist capacity was significantly associated with either outcome. Marked geographic variation in ADHD medication use and diagnoses persists in Denmark despite a uniform healthcare framework, and appears largely unexplained by the system‐level factors examined.
- 18 February 2026
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 40 (3) , 361-363
The Black Box of Antidepressant Treatment Persistence in Children and Adolescents
- 18 February 2026
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 40 (3) , 361-363
The Black Box of Antidepressant Treatment Persistence in Children and Adolescents
- Open Access
- 10 February 2026
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 35 (5) , 1667-1675
Trends and incidence rates of neurodevelopmental disorders in Danish children and adolescents 2000–2024
Background Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD) are prevalent neurodevelopmental disorders with long-term consequences. Recognition is essential but often delayed, particularly in females. Many cases are not captured in national registers, though many ADHD are often identifiable through prescriptions. We examined age- and sex-specific incidence and temporal trends in ASD and ADHD diagnosis in Denmark from 2000 to 2024 and assessed how including prescription data affects ADHD estimates. Methods A cohort of all children residing in Denmark from 2000 to 2024 (n = 2.8 million) was followed until age 18 or December 31, 2024. Using nationwide registers, we identified diagnoses of ASD and ADHD. For ADHD, we extended the definition to include ADHD-specific prescriptions. We estimated age- and sex-specific incidence rates (IRs), cumulative incidence at each 1-year age point, and trends by birth cohort. Results Among 2.8 million children, 60,432 were diagnosed with ASD and 102,051 with ADHD. Incidence rates increased for both conditions, with a steeper rise among females. By age 18, cumulative incidence was 6.5% (95% confidence intervals (CI) 6.5–6.6) in males and 3.9% (95% CI 3.8-4.0) in females for ASD, and 9.8% (95% CI 9.8–9.9) and 7.4% (95% CI 7.3–7.5) for ADHD. Although rates remained higher in males, the sex gap narrowed substantially, particularly for ADHD. Including ADHD-specific prescriptions raised cumulative ADHD incidence by age 18 from 6.9% (95% CI 6.8–6.9) to 8.7% (95% CI 8.6–8.7). Conclusion The incidence of ASD and ADHD has risen substantially in Denmark over the past two decades, most pronounced among girls, narrowing the historical sex gap. Incorporating prescription data increased ADHD incidence estimates notably, underscoring the importance of broader case definitions in epidemiological research.
- 10 February 2026
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 35 (5) , 1667-1675
Open AccessTrends and incidence rates of neurodevelopmental disorders in Danish children and adolescents 2000–2024
Background Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD) are prevalent neurodevelopmental disorders with long-term consequences. Recognition is essential but often delayed, particularly in females. Many cases are not captured in national registers, though many ADHD are often identifiable through prescriptions. We examined age- and sex-specific incidence and temporal trends in ASD and ADHD diagnosis in Denmark from 2000 to 2024 and assessed how including prescription data affects ADHD estimates. Methods A cohort of all children residing in Denmark from 2000 to 2024 (n = 2.8 million) was followed until age 18 or December 31, 2024. Using nationwide registers, we identified diagnoses of ASD and ADHD. For ADHD, we extended the definition to include ADHD-specific prescriptions. We estimated age- and sex-specific incidence rates (IRs), cumulative incidence at each 1-year age point, and trends by birth cohort. Results Among 2.8 million children, 60,432 were diagnosed with ASD and 102,051 with ADHD. Incidence rates increased for both conditions, with a steeper rise among females. By age 18, cumulative incidence was 6.5% (95% confidence intervals (CI) 6.5–6.6) in males and 3.9% (95% CI 3.8-4.0) in females for ASD, and 9.8% (95% CI 9.8–9.9) and 7.4% (95% CI 7.3–7.5) for ADHD. Although rates remained higher in males, the sex gap narrowed substantially, particularly for ADHD. Including ADHD-specific prescriptions raised cumulative ADHD incidence by age 18 from 6.9% (95% CI 6.8–6.9) to 8.7% (95% CI 8.6–8.7). Conclusion The incidence of ASD and ADHD has risen substantially in Denmark over the past two decades, most pronounced among girls, narrowing the historical sex gap. Incorporating prescription data increased ADHD incidence estimates notably, underscoring the importance of broader case definitions in epidemiological research.
- Open Access
- 27 January 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (1) , e0339721
Defining the population of adolescents in need of comprehensive transitional care based on diagnosis, visit frequency, and disease complexity
Healthcare transition from pediatrics to adult care is a critical yet challenging process for adolescents with long-term medical conditions. This population-based cohort study aims to present a replicable method to identify and quantify adolescents in need of comprehensive transitional care. Using data from Danish national health registers, disease complexity was categorized by expert clinicians based on diagnoses indicative of a need for comprehensive transitional care and transfer to specialized adult healthcare. The study identified 4,677 adolescents requiring comprehensive transitional care from a background population of 418,994 Danish adolescents aged 16–17 years, corresponding to 1.1%. Analysis of outpatient visit data from tertiary hospitals revealed variability in the proportion of adolescents with comprehensive transitional care needs across Denmark’s four tertiary hospitals. For instance, 11.6% of outpatient visits at Aalborg University Hospital involved a comprehensive transition-requiring diagnosis, compared to 26.7% at Copenhagen University Hospital. While the method is intentionally specific and focused on adolescents with the most complex conditions, it offers a scalable framework that could be applied across broader clinical settings. We illustrate this by also applying the method within a pediatric department-based setting. This study provides al replicable framework to assess transition care needs at a population level, primarily identifying adolescents with the most complex conditions. Broader implementation across clinical settings may refine and inform equitable transitional strategies.
- 27 January 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (1) , e0339721
Open AccessDefining the population of adolescents in need of comprehensive transitional care based on diagnosis, visit frequency, and disease complexity
Healthcare transition from pediatrics to adult care is a critical yet challenging process for adolescents with long-term medical conditions. This population-based cohort study aims to present a replicable method to identify and quantify adolescents in need of comprehensive transitional care. Using data from Danish national health registers, disease complexity was categorized by expert clinicians based on diagnoses indicative of a need for comprehensive transitional care and transfer to specialized adult healthcare. The study identified 4,677 adolescents requiring comprehensive transitional care from a background population of 418,994 Danish adolescents aged 16–17 years, corresponding to 1.1%. Analysis of outpatient visit data from tertiary hospitals revealed variability in the proportion of adolescents with comprehensive transitional care needs across Denmark’s four tertiary hospitals. For instance, 11.6% of outpatient visits at Aalborg University Hospital involved a comprehensive transition-requiring diagnosis, compared to 26.7% at Copenhagen University Hospital. While the method is intentionally specific and focused on adolescents with the most complex conditions, it offers a scalable framework that could be applied across broader clinical settings. We illustrate this by also applying the method within a pediatric department-based setting. This study provides al replicable framework to assess transition care needs at a population level, primarily identifying adolescents with the most complex conditions. Broader implementation across clinical settings may refine and inform equitable transitional strategies.
- Open Access
- 24 December 2025
- Published by Elsevier in International Journal of Hygiene and Environmental Health
- Vol. 272, 114734
In utero and early childhood exposure to per- and polyfluoroalkyl substances and use of antibiotics in children from the Odense Child Cohort: A Danish cohort study
- 24 December 2025
- Published by Elsevier in International Journal of Hygiene and Environmental Health
- Vol. 272, 114734
Open AccessIn utero and early childhood exposure to per- and polyfluoroalkyl substances and use of antibiotics in children from the Odense Child Cohort: A Danish cohort study
- 24 October 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (2) , 493-499
Psychotropic Drug Use Among Danish Care Home Residents During and After the COVID ‐19 Pandemic
Background: The COVID‐19 pandemic and related measures led to social isolation and disrupted daily routines for care home residents, potentially harming their mental health. This study explored changes in incident psychotropic drug use among Danish care home residents during and after the pandemic. Methods: We conducted an interrupted time series analysis on all individuals admitted to Danish care homes between 2015 and 2023 ( n = 128,915). We compared monthly rates of incident psychotropic drug use during and after the COVID‐19 pandemic with predictions from the pre‐pandemic trends, estimating the excess number of cases for each period. Results: At care home admission, residents had a median age of 85 years (interquartile range: 78–90), and 51% used psychotropic drugs. During the pandemic, incident psychotropic drug use exceeded levels expected from the pre‐pandemic trend (179 excess users/10,000 residents; 95% confidence interval (CI): 72–286), with small increases for antidepressants (68/10,000; 95% CI: 7.9–128) and antipsychotics (81/10,000; 95% CI: 36–126). In the post‐pandemic period, overall incident psychotropic use remained higher than expected from the pre‐pandemic trend (343/10,000; 95% CI: 29–656). Although on a declining trend, incidence rates for antidepressants and Z‐drugs were slightly elevated in the post‐pandemic period (antidepressants: 237/10,000; 95% CI: 83–390; Z‐drugs: 60/10,000; 95% CI: 23–98), while incident antipsychotic use returned to the pre‐pandemic trend. Benzodiazepines and melatonin showed no substantial changes. Among incident psychotropic drug users during and after the pandemic, 58% had recent exposure to another psychotropic drug class, and 71% continued treatment beyond 6 months. Conclusions: Incident psychotropic drug use among Danish care home residents increased during the COVID‐19 pandemic and remained slightly elevated afterward. This warrants closer scrutiny of prescribing practices and highlights the need for targeted interventions to optimize psychotropic drug use in the post‐pandemic era.
- 24 October 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (2) , 493-499
Psychotropic Drug Use Among Danish Care Home Residents During and After the COVID ‐19 Pandemic
Background: The COVID‐19 pandemic and related measures led to social isolation and disrupted daily routines for care home residents, potentially harming their mental health. This study explored changes in incident psychotropic drug use among Danish care home residents during and after the pandemic. Methods: We conducted an interrupted time series analysis on all individuals admitted to Danish care homes between 2015 and 2023 ( n = 128,915). We compared monthly rates of incident psychotropic drug use during and after the COVID‐19 pandemic with predictions from the pre‐pandemic trends, estimating the excess number of cases for each period. Results: At care home admission, residents had a median age of 85 years (interquartile range: 78–90), and 51% used psychotropic drugs. During the pandemic, incident psychotropic drug use exceeded levels expected from the pre‐pandemic trend (179 excess users/10,000 residents; 95% confidence interval (CI): 72–286), with small increases for antidepressants (68/10,000; 95% CI: 7.9–128) and antipsychotics (81/10,000; 95% CI: 36–126). In the post‐pandemic period, overall incident psychotropic use remained higher than expected from the pre‐pandemic trend (343/10,000; 95% CI: 29–656). Although on a declining trend, incidence rates for antidepressants and Z‐drugs were slightly elevated in the post‐pandemic period (antidepressants: 237/10,000; 95% CI: 83–390; Z‐drugs: 60/10,000; 95% CI: 23–98), while incident antipsychotic use returned to the pre‐pandemic trend. Benzodiazepines and melatonin showed no substantial changes. Among incident psychotropic drug users during and after the pandemic, 58% had recent exposure to another psychotropic drug class, and 71% continued treatment beyond 6 months. Conclusions: Incident psychotropic drug use among Danish care home residents increased during the COVID‐19 pandemic and remained slightly elevated afterward. This warrants closer scrutiny of prescribing practices and highlights the need for targeted interventions to optimize psychotropic drug use in the post‐pandemic era.
- Open Access
Regional variation in ADHD treatment and diagnosis in Denmark
Introduction: Attention-deficit/hyperactivity disorder (ADHD) treatment and diagnoses show marked international and regional variation, not fully explained by underlying morbidity. In Denmark, earlier studies reported substantial regional differences, raising concerns about inequities in access to care. We examined nationwide patterns of ADHD medication use and diagnosis in 2024 and assessed system-level factors potentially contributing to geographic variation. Methods: We conducted a register-based cross-sectional study of all Danish residents aged 4-17 years in 2024, using data from the National Patient Register, National Prescription Registry, Civil Registration System, and administrative sources. Pharmacological treatment of ADHD was defined as at least one redeemed prescription for ADHD drugs, while ADHD diagnoses were defined as at least one hospital contact with International Classification of Diseases, 10th revision codes F90.x/F98.8. Prevalence estimates were calculated overall and stratified by subgroups of sex and age. Associations with municipal socioeconomic index, regional hospital waiting times, and private child psychiatrist capacity were evaluated using Spearman’s rank correlations and regression analyses. Results: Among 4-17-year-olds, ADHD medication prevalence ranged sixfold across municipalities (9.6-58 per 1,000). ADHD diagnoses showed parallel patterns (15-74 per 1,000). Variation was largest among adolescents (more than sevenfold). Municipal socioeconomic status was weakly and inversely correlated with medication use (ρ = -0.20, p = 0.049), but not diagnoses. Regional waiting times and specialist capacity varied but showed no significant associations with the prevalence of either medication use or diagnoses. Conclusion: Marked geographic variation in ADHD medication use and diagnoses persists in Denmark despite a uniform healthcare framework. Observed differences were only weakly related to socioeconomic context, specialist capacity, or waiting times, suggesting that the unwarranted variation is driven by other factors. Ensuring equitable access will require addressing both structural resources and local practice variation. Significant Outcomes: ADHD medication and diagnosis prevalence among Danish children and adolescents in 2024 varied more than sixfold across municipalities. Socioeconomic context, specialist capacity, and waiting times explained little of the observed geographic variation. Limitations: Waiting time data were available only for hospital-based services, excluding the referral phase and private practices. Specialist capacity was measured only for private psychiatrists under agreements with the public health insurance system, limiting coverage of capacity for public hospitals and private non-contracted services. Regional-level analyses were constrained by the small number of regions (n=5), reducing statistical power and precision.
Open AccessRegional variation in ADHD treatment and diagnosis in Denmark
Introduction: Attention-deficit/hyperactivity disorder (ADHD) treatment and diagnoses show marked international and regional variation, not fully explained by underlying morbidity. In Denmark, earlier studies reported substantial regional differences, raising concerns about inequities in access to care. We examined nationwide patterns of ADHD medication use and diagnosis in 2024 and assessed system-level factors potentially contributing to geographic variation. Methods: We conducted a register-based cross-sectional study of all Danish residents aged 4-17 years in 2024, using data from the National Patient Register, National Prescription Registry, Civil Registration System, and administrative sources. Pharmacological treatment of ADHD was defined as at least one redeemed prescription for ADHD drugs, while ADHD diagnoses were defined as at least one hospital contact with International Classification of Diseases, 10th revision codes F90.x/F98.8. Prevalence estimates were calculated overall and stratified by subgroups of sex and age. Associations with municipal socioeconomic index, regional hospital waiting times, and private child psychiatrist capacity were evaluated using Spearman’s rank correlations and regression analyses. Results: Among 4-17-year-olds, ADHD medication prevalence ranged sixfold across municipalities (9.6-58 per 1,000). ADHD diagnoses showed parallel patterns (15-74 per 1,000). Variation was largest among adolescents (more than sevenfold). Municipal socioeconomic status was weakly and inversely correlated with medication use (ρ = -0.20, p = 0.049), but not diagnoses. Regional waiting times and specialist capacity varied but showed no significant associations with the prevalence of either medication use or diagnoses. Conclusion: Marked geographic variation in ADHD medication use and diagnoses persists in Denmark despite a uniform healthcare framework. Observed differences were only weakly related to socioeconomic context, specialist capacity, or waiting times, suggesting that the unwarranted variation is driven by other factors. Ensuring equitable access will require addressing both structural resources and local practice variation. Significant Outcomes: ADHD medication and diagnosis prevalence among Danish children and adolescents in 2024 varied more than sixfold across municipalities. Socioeconomic context, specialist capacity, and waiting times explained little of the observed geographic variation. Limitations: Waiting time data were available only for hospital-based services, excluding the referral phase and private practices. Specialist capacity was measured only for private psychiatrists under agreements with the public health insurance system, limiting coverage of capacity for public hospitals and private non-contracted services. Regional-level analyses were constrained by the small number of regions (n=5), reducing statistical power and precision.